MAIA Biotechnology, Inc. is a cutting-edge, early stage biotech company, dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.  A privately-held company based in Chicago, MAIA is led by a passionate, principled and dynamic Management Team with significant drug development experience, committed to advancing promising agents into trials in humans in the next 2-4 years.

MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.



Our Pipeline of Investigational Drugs

DGD-1202

DGD-1202, a mtEGFR degrader, has been designed to be selectively effective in inducing phosphorylated-EGFR degradation in tumors, including tyrosine kinase...

THIO

THIO (6-thio-dG) has been designed to target tumor cell DNA and cause damage to DNA ends (telomeres), resulting in the...

MJC13

MJC13 targets the regulation of androgen receptor (AR) by binding to a recently identified regulatory surface on AR (BF3). MJC13 is...

GMC1

GMC1 is a FKBP52 co-chaperone-inhibitor for prostate cancer. GMC1 has been designed to engage a new pharmacologic target, FKBP52 (FK506...